| __timestamp | Agios Pharmaceuticals, Inc. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 10811000 |
| Thursday, January 1, 2015 | 35992000 | 33001000 |
| Friday, January 1, 2016 | 50714000 | 64936000 |
| Sunday, January 1, 2017 | 71124000 | 99909000 |
| Monday, January 1, 2018 | 114145000 | 127724000 |
| Tuesday, January 1, 2019 | 132034000 | 161524000 |
| Wednesday, January 1, 2020 | 149070000 | 182933000 |
| Friday, January 1, 2021 | 121445000 | 219982000 |
| Saturday, January 1, 2022 | 121673000 | 278139000 |
| Sunday, January 1, 2023 | 119903000 | 309799000 |
| Monday, January 1, 2024 | 156784000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing operational expenses is crucial for sustainable growth. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Ultragenyx Pharmaceutical Inc. and Agios Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Ultragenyx consistently outpaced Agios in SG&A spending, with a notable increase of over 180% from 2014 to 2023. In contrast, Agios saw a more modest rise of approximately 530% in the same timeframe. This disparity highlights Ultragenyx's aggressive investment in administrative and sales functions, potentially reflecting a strategy focused on rapid expansion and market penetration. Meanwhile, Agios's steadier growth in SG&A expenses suggests a more conservative approach, possibly prioritizing cost efficiency. Understanding these trends provides valuable insights into each company's strategic priorities and operational efficiency.
Breaking Down SG&A Expenses: Eli Lilly and Company vs Agios Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Vertex Pharmaceuticals Incorporated and Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Pharming Group N.V. or Agios Pharmaceuticals, Inc.
Ultragenyx Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Perrigo Company plc Trends and Insights
Selling, General, and Administrative Costs: Ultragenyx Pharmaceutical Inc. vs Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Xenon Pharmaceuticals Inc. and Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Wave Life Sciences Ltd.
Selling, General, and Administrative Costs: Agios Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.